Related Experiment Videos
Adenoviral gene therapy
Stephan A Vorburger1, Kelly K Hunt
1Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Abstract:
As of May 2001, 532 gene therapy protocols had been approved for evaluation in clinical trials; however, only five of those had been evaluated in phase III clinical trials. Among the most commonly used vectors for the delivery of genetic material into human cells are the adenoviruses. Remarkable progress has been made with these vectors in the last decade, but some shortcomings continue to challenge investigators. The newly acquired knowledge of the adenoviral life cycle and the positive outcomes from phase II clinical trials have led to the application of vectors engineered to selectively target tumor tissue under controlled promoters.
Insights
Gene therapy trials show promise, with adenoviruses being key delivery vectors. Engineered adenoviruses now target tumors selectively, advancing clinical applications.
Area of Science:
- Biomedical research
- Molecular biology
- Oncology
Background:
- Over 500 gene therapy protocols were approved by May 2001, but few reached Phase III trials.
- Adenoviruses are frequently used vectors for gene delivery in human cells.
- Despite progress, adenoviral vectors have limitations in gene therapy.
Purpose of the Study:
- To review the progress and challenges of adenoviral vectors in gene therapy.
- To highlight the development of engineered adenoviruses for targeted tumor delivery.
- To discuss the application of these advanced vectors in clinical settings.
Main Methods:
- Review of approved gene therapy protocols and clinical trial phases.
- Analysis of adenoviral vector applications and advancements.
- Examination of engineered adenoviruses for tumor-specific targeting.
Main Results:
- Only five out of 532 gene therapy protocols had reached Phase III trials by May 2001.
- Adenoviral vectors have shown significant progress but still face challenges.
- Engineered adenoviruses demonstrate selective tumor targeting under controlled promoters.
Conclusions:
- Adenoviral vectors are crucial for gene delivery, with ongoing improvements.
- Engineered adenoviruses offer enhanced specificity for tumor targeting in gene therapy.
- Advancements in adenoviral vector technology are paving the way for more effective cancer treatments.